Tags

Type your tag names separated by a space and hit enter

Catechol-O-methyltransferase valine158methionine polymorphism moderates methylphenidate effects on oppositional symptoms in boys with attention-deficit/hyperactivity disorder.
Biol Psychiatry 2011; 70(3):216-21BP

Abstract

BACKGROUND

The catechol-O-methyltransferase enzyme plays a key role in the function of prefrontal cortex, accounting for most of the degradation of dopamine. Previous studies have documented the improvement of oppositional symptoms in attention-deficit/hyperactivity disorder (ADHD) patients with methylphenidate (MPH) treatment. However, the effect of the COMT gene in the response to MPH on oppositional symptoms has not been investigated.

METHODS

A total of 251 children with ADHD fulfilled inclusion criteria to participate in the study. Dosages of short-acting MPH were augmented until no further clinical improvement was detected or until there were significant adverse events (MPH dose always > .3 mg/kg/day). The outcome measure was the parent-rated oppositional subscale of the Swanson, Nolan and Pelham Scale-Version IV (SNAP-IV). The scale was applied by child psychiatrists blinded to genotype at baseline and in the first and third months. The COMT valine158methionine polymorphism was genotyped by polymerase chain reaction based methods.

RESULTS

We detected significant improvement in SNAP-IV oppositional scores from baseline to the first and three months of treatment [n = 112; F(2,231) = 5.35, p = .005]. A significant effect of the presence of methionine allele in oppositional defiant disorder scores during treatment [F(1,148) = 5.02, p = .027] and a significant interaction between the methionine allele and treatment over time for the SNAP-IV oppositional scores during this period of treatment [F(2,229) = 6.40, p = .002] were both observed.

CONCLUSIONS

These results suggest an effect of the COMT genotype on the trajectory of oppositional defiant disorder symptoms improvement with MPH treatment in boys with ADHD.

Authors+Show Affiliations

Genetics Department, Federal University of Rio Grande do Sul, Porto Alegre, Brazil.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

21550019

Citation

Salatino-Oliveira, Angélica, et al. "Catechol-O-methyltransferase Valine158methionine Polymorphism Moderates Methylphenidate Effects On Oppositional Symptoms in Boys With Attention-deficit/hyperactivity Disorder." Biological Psychiatry, vol. 70, no. 3, 2011, pp. 216-21.
Salatino-Oliveira A, Genro JP, Zeni C, et al. Catechol-O-methyltransferase valine158methionine polymorphism moderates methylphenidate effects on oppositional symptoms in boys with attention-deficit/hyperactivity disorder. Biol Psychiatry. 2011;70(3):216-21.
Salatino-Oliveira, A., Genro, J. P., Zeni, C., Polanczyk, G. V., Chazan, R., Guimarães, A. P., ... Hutz, M. H. (2011). Catechol-O-methyltransferase valine158methionine polymorphism moderates methylphenidate effects on oppositional symptoms in boys with attention-deficit/hyperactivity disorder. Biological Psychiatry, 70(3), pp. 216-21. doi:10.1016/j.biopsych.2011.03.025.
Salatino-Oliveira A, et al. Catechol-O-methyltransferase Valine158methionine Polymorphism Moderates Methylphenidate Effects On Oppositional Symptoms in Boys With Attention-deficit/hyperactivity Disorder. Biol Psychiatry. 2011 Aug 1;70(3):216-21. PubMed PMID: 21550019.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Catechol-O-methyltransferase valine158methionine polymorphism moderates methylphenidate effects on oppositional symptoms in boys with attention-deficit/hyperactivity disorder. AU - Salatino-Oliveira,Angélica, AU - Genro,Julia P, AU - Zeni,Cristian, AU - Polanczyk,Guilherme V, AU - Chazan,Rodrigo, AU - Guimarães,Ana P, AU - Callegari-Jacques,Sidia M, AU - Rohde,Luis A, AU - Hutz,Mara H, Y1 - 2011/05/06/ PY - 2010/05/04/received PY - 2011/03/10/revised PY - 2011/03/12/accepted PY - 2011/5/10/entrez PY - 2011/5/10/pubmed PY - 2011/12/13/medline SP - 216 EP - 21 JF - Biological psychiatry JO - Biol. Psychiatry VL - 70 IS - 3 N2 - BACKGROUND: The catechol-O-methyltransferase enzyme plays a key role in the function of prefrontal cortex, accounting for most of the degradation of dopamine. Previous studies have documented the improvement of oppositional symptoms in attention-deficit/hyperactivity disorder (ADHD) patients with methylphenidate (MPH) treatment. However, the effect of the COMT gene in the response to MPH on oppositional symptoms has not been investigated. METHODS: A total of 251 children with ADHD fulfilled inclusion criteria to participate in the study. Dosages of short-acting MPH were augmented until no further clinical improvement was detected or until there were significant adverse events (MPH dose always > .3 mg/kg/day). The outcome measure was the parent-rated oppositional subscale of the Swanson, Nolan and Pelham Scale-Version IV (SNAP-IV). The scale was applied by child psychiatrists blinded to genotype at baseline and in the first and third months. The COMT valine158methionine polymorphism was genotyped by polymerase chain reaction based methods. RESULTS: We detected significant improvement in SNAP-IV oppositional scores from baseline to the first and three months of treatment [n = 112; F(2,231) = 5.35, p = .005]. A significant effect of the presence of methionine allele in oppositional defiant disorder scores during treatment [F(1,148) = 5.02, p = .027] and a significant interaction between the methionine allele and treatment over time for the SNAP-IV oppositional scores during this period of treatment [F(2,229) = 6.40, p = .002] were both observed. CONCLUSIONS: These results suggest an effect of the COMT genotype on the trajectory of oppositional defiant disorder symptoms improvement with MPH treatment in boys with ADHD. SN - 1873-2402 UR - https://www.unboundmedicine.com/medline/citation/21550019/Catechol_O_methyltransferase_valine158methionine_polymorphism_moderates_methylphenidate_effects_on_oppositional_symptoms_in_boys_with_attention_deficit/hyperactivity_disorder_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0006-3223(11)00275-7 DB - PRIME DP - Unbound Medicine ER -